Kantarjian et al53 assessed the efficacy and security of dasatinib, as when compared with imatinib, for the very first-line procedure of CML-CP. Five hundred and nineteen clients with recently diagnosed CML-CP had been randomly assigned to acquire dasatinib in a dose of a hundred mg at the time each day https://emersong296wbf0.mappywiki.com/user